Vistagen Therapeutics, Inc. (VTGN)
| Previous close | 4.7000 |
| Open | 4.7100 |
| Bid | 4.6700 x 200 |
| Ask | 4.7400 x 300 |
| Day's range | 4.6500 - 4.8200 |
| 52-week range | 1.6200 - 24.7100 |
| Volume | |
| Avg. volume | 267,112 |
| Market cap | 127.186M |
| Beta (5Y monthly) | 0.81 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.9600 |
| Earnings date | 26 June 2024 - 01 July 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 13.00 |
Business WireVistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue
SOUTH SAN FRANCISCO, Calif., April 25, 2024--Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced positive results from a Phase 2A pilot study of PH15, an investigational pherine nasal spray, for improvement of psychomotor impairment caused by mental fatigue. PH15 demonstrated a statistically significant improvement in reaction time compared to placebo a
Business WireVistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference
SOUTH SAN FRANCISCO, Calif., April 09, 2024--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that it will present posters detailing clinical trial data for fasedienol, an investigational pherine candidate in Phase 3 development for the acute treatment of social anxiety disorder (SAD), and PH80, a Phase 2 investigational pherine c
Business WireVistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2
SOUTH SAN FRANCISCO, Calif., April 01, 2024--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that it has enrolled the first patient in its PALISADE-3 Phase 3 trial of fasedienol, an investigational pherine candidate in development for the acute treatment of social anxiety disorder (SAD).
